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CASE REPORT
DISSEMINATED CUTANEOUS CRYPTOCOCCOSIS IN A PATIENT WITH AIDS
Sandra Lopes Mattos e DINATO(1), Marcelo Mattos e DINATO(2), Carla Patrícia NAKANISHI(3), José Roberto Paes de ALMEIDA(4) & Ney ROMITI(5)
SUMMARY
The authors study a patient carrying Aids, with exuberant dermatological manifestations of cryptococcosis. They stress the
therapeutic effectiveness of short-term amphotericin B. The authors reviewed cases of cutaneous infection with Cryptococcus
reported in the national and international literature, verifying that the frequency has increased with the AIDS epidemic. Also, they
discuss about the differential diagnosis with some cases of dermatosis, particularly with the disseminated giant molluscum
contagiosum. In relation to the therapy, they affirm that the choice of drug depends on the organ involved, as well as the immune
state of the patient.
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INTRODUCTION
Cryptococcosis, also known as torulosis, Busse - Buschke’s disease
and European blastomycosis is a cosmopolitan illness, with opportunist
behavior2,11,12,14,20,24,29.
It is a fungal systemic infection caused by Cryptococcus
neoformans, characterized as a species of encapsulated yeasts which,
based on the capsule structure, were grouped into two varieties that
included five serotypes. C. neoformans var. neoformans including
serotypes A, D and AD, and C. neoformans var. gatti contained strains
with serotypes B and C. Based on DNA genotyping methods, several
changes have been proposed. According to that, serotype A would be
classified as a separate variety, C. neoformans, var. grubii. In AIDS
patients, the vast majority of isolates are serotype A (var.
grubii)2,6,7,19,20,21.
Many cases described are associated to the immunosuppression,
due to lymphoma17, chronic leukemia23,24, transplants of organs11, use
of corticosteroid27,33, immunosuppressive drugs14,27, systemic lupus
erythematosus28, diabetes mellitus14,23, Cushing’s syndrome5 and, more
recently, related with acquired immunodeficiency syndrome
(Aids)1,2,11,15,25,29.
With the advent of AIDS, the number of cases of cryptococcosis
has increased: from 1982 to 1991, its incidence almost quadrupled in
relation to the period from 1953 to 1981. In this syndrome, the incidence
rates have reached 10% in the developed countries (USA, England,
Italy, Australia and Germany), while in countries in development, they
vary between 20-81%16.
In Brazil, a study9 of the illnesses associated to AIDS, from 1980
to 1999, in 157,775 sick people, showed a reduction in the incidence
of all of them, compared to the initial period (1980-1988) and the final
period (1998-1999). Candidiasis was found (59.2%), followed by
tuberculosis (25.5%). In 4.5% of the cases, cryptococcosis had been
detected, the majority being in men with more education, who are
from the southeastern region and among men that had acquired the
base illness by sanguineous transmission (heterosexual).
On the other hand, neurocryptococcosis, a fungal illness of high
mortality8, represents the second most common infection of the central
nervous system in patients with AIDS. In Santos, during the period of
1/1/1984 to 9/30/2001, the Municipal Health Secretariat, registered
114 (2.6%) cases of cryptococcosis in the central nervous system in a
total of 4,368 cases of AIDS in adults31.
In relation to the cutaneous lesions of cryptococcosis, it can be
confirmed that it is rare, occurring in only 5%-15% of the patients
with systemic form of the illness11,12. In the two Brazilian studies cited
above, there is no reference about the frequency of the cutaneous form
of this deep fungal infection8,9.
The objective of our study is to report on the exuberant dermatological
manifestations of cryptococcosis in patient with AIDS, as well as the
therapeutical effectiveness of short-term amphotericin B.
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CASE REPORT
RPS, 38 year-old, white male, single, autonomous worker, a native
of Santos, São Paulo.
The patient sought the services of the Hospital Guilherme Álvaro
(HGA) day clinic, complaining of about fifteen days of continuous
headache, intermittent fever and lightly pruriginous injuries, which
had begun in the face, with posterior centripetal evolution and spread
to the entire tegument in a few days. Spontaneously, he informed us he
has been carrying the virus of AIDS, without specific treatment for
three months, because he gave up the treatment. Previously, he was
treated for pulmonary tuberculosis.
During the dermatological examination, well-defined papules and
nodules, erythematous, some with generalized centralis depression,
were noticed, being more exuberant, however, in the face, anterior and
posterior region of the trunk (Fig. 1,2,3).
During the physical examination, it was observed that the patient
had lost weight, was in a poor general state, feverish, had slightly
discoloured mucosa, generalized adenopathy, rigidity in the nape of
the neck and hepatoesplenomegaly (palpable liver three cm below the
right costal margin and palpable spleen four cm below the left costal
margin).
On this occasion, he was hospitalized for some complementary
examinations, for the purpose of diagnostic briefing, his initial
hypotheses having had included cryptococcosis, histoplasmosis,
paracoccidioidomycosis and disseminated giant molluscum
contagiosum.
A biopsy of the cutaneous injury was made, and the
histopathological examination, by optical microscopy with
hematoxylin-eosin, revealed epidermis with acantholysis and dermis
with agglomerate presence of vacuolized cells. The PAS and Grocott
staining (Fig. 4, 5, 6) had been positive for encapsulated yeast cells,
Fig. 1 - Exuberant injury in the face, similar to giant molluscum contagiosum.
Fig. 2 - Injuries in the anterior region of the thorax.
Fig. 3 - Some injuries with centralis depression in the left shoulder. Fig. 6 - Grocott 100x. Yeast cells with multiple budding.
Fig. 5 - Grocott 40x. Presence of innumerable yeast cells of black color.
Fig. 4 - PAS 100x. Presence of innumerable encapsulated yeast cells.
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suggesting Cryptococcus neoformans. Also, other exams were
performed: Hemoculture - positive for Cryptococcus neoformans and
Culture of the cerebrospinal fluid - positive for Cryptococcus
neoformans (Instituto Adolfo Lutz).
The initial hematological examinations had shown: Hb: 6.2 g/dL,
Ht: 20 mL eritroc/dL, leukocytes: 1,800/mm3, platelets: 200,000/mm3,
creatinine: 0.9 mg/dL and CD4: 2 cells/mm3.
After the diagnostic confirmation, treatment for cryptococcosis with
endovenous amphotericin B in increasing doses was initiated and the
therapeutic schema for AIDS (3TC and d4T) restarted. During his
hospitalization, the patient underwent a blood transfusion because of
his anemic condition. Alteration of renal function (creatinine: 1.9 mg/
dL) developed, after the beginning of the treatment with amphotericin
B, a probable cause of this adverse effect, which was normalized later.
Some common collateral effects of this drug, such as tremors and chills,
also occurred with the patient. In relation to neurological and cutaneous
forms, there was an improvement in the headache and development of
injuries of the skin. He was released with accumulative dose of one g
of amphotericin B, with fluconazole being prescribed for daily use,
after release from the hospital. On that occasion he was reported to
CRAIDS (AIDS Reference Center) where we found some examinations
on his chart: 1) Direct mycological (liquor) - Cryptococcus spp. research
- Positive; 2) Latex agglutination reaction for the Cryptococcus
neoformans in liquor - Reagent (Instituto Adolfo Lutz). Also, we found
a request for a new hospitalization, this time, to “Irmandade da Santa
Casa de Misericórdia de Santos”, due to the occurrence of headache,
vomiting, right-side hemiparesis, dysphasia and mental confusion, with
the diagnostic hypothesis of neurotoxoplasmosis. Consulting the chart
from this hospital, we found a computerized tomography of the cranium
whose contrast showed: slight dilatation of the infra and supratentorial
ventricular system, with asymmetry of lateral ventricules, their being
larger to the left, and in the left temporoparietal hipoattenuation zone,
with effacement of cortical sulci; with diagnostic hypothesis of: Left
temporofrontal ischemic focus? Infectious process? During this
hospitalization period, the previous medicines were maintained and
systemic corticosteroid, sulfadiazine and piremetamine introduced, the
patient being released after 10 days, in a conscious state, although still
having right-side hemiparesis. The patient was again sent to CRAIDS,
when the clinical picture was much worse, requiring new hospitalization
and returning to HGA 16 months after his first admittance into our
service, with the same therapeutic procedure being maintained.
On that occasion, his relatives informed that the patient had not
taken the prescribed medicine regularly.
Intercurrent ailments were the following: oral candidiasis, urinary
infection, and B and C hepatitis. There was no reappearance of
cutaneous lesions, and in the laboratory, the hemoculture and the liquor
culture were negative for fungi.
He stayed in that hospital for 35 days until his death, always in
grave condition, with right-side hemiparesis, dyslalia and prolonged
periods of mental confusion. The causa-mortis was the multiple organ
failure. Necropsy could not be performed, due to the unavailability, at
that time, in the city.
In conclusion, the strict chart observation did not allowed us to
make a definite neurological diagnosis. However, we point out that the
purpose of this work was to describe an unusual form of skin
manifestation of the disease, as well as its specific evolution.
DISCUSSION
The first case of cryptococcosis infection in human beings was
reported in 1894, by Busse, in Germany. Cryptococcus neoformans
was isolated for the first time by Sanfelice in this same year, from
spoiled fruit juice2,19,20. In Brazil, the first publication was made by
Almeida & Lacaz, in 194120.
Cryptococcus neoformans is a ubiquitous fungus, which belongs
to the Basidiomycota Phylum and Tremellomycetidae Family. It is found
in the ground and in tissues, secretions and excrements of animals and
of the human beings. It is not contagious among humans2,19,20. Its
transmission to humans occurs, mainly, by inhalation of non-
encapsulated yeast forms or of those with thin capsules, transmitted,
particularly, from contact with excrement of pigeons12,26. This patient
reported the habit of going to caves, where conditions could be more
compatible for histoplasmosis.
In the pulmonary parenchyma, the fungus can cause tissular and
immune reactions, that normally block the infection. When it
disseminates, this occurs through the hematogenic duct. It is important
to note that, this fungus still has unexplained neurotropisms12,29.
However, KUMAZAWA et al. (1998) observed, through serial magnetic
resonance imaging, some radiological aspects in cryptococcosis of the
central nervous system, that reflect the pathological mechanism of
invasion by the fungi18.
Two factors are basic in the pathogenesis of this deep mycosis: the
virulence of fungus and the imunological response of the host. The
resistence is so important that, many times, cryptococcosis can be the
first sign of immunodepression, being one of the main illnesses
associated to AIDS8,9,31.
The incidence of the infection by Cryptococcus in patients with
AIDS depends on determinative factors, particularly of CD4-cell counts
below 100 cells/mL32. The patient in this study presented levels of
CD4 of 2 cells/mL. It is important to remember that corticotherapy is
essential for the treatment of certain illnesses associated to AIDS;
however, it can predispose the infection of Cryptococcus2.
The literature shows that cryptococcosis occurs more frequently
in men (about 70% of the cases) and in adults (majority between 30
and 60 years)2, data which corresponds to that of this patient (man of
38 years). The occurrence of cryptococcosis in children with AIDS
corresponds 1%1.
Cryptococcosis reaches several organs; when associated to AIDS,
it appears in more than one location, in up to 50% of the cases2, and
this was also the case with the patient studied here.
Neurocryptococcosis represents the second most common infection
in the central nervous system of patients with AIDS, a fact which has
raised the mortality rate8. On the other hand, it is the most frequent
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clinical manifestation of the illness (70 a 89.5%), mainly presenting
chronic headache, fever, vomiting, rigidity in the nape of the neck and
mental alterations, with torpor or coma2 possibly developing. Some of
these cited symptoms or signs had been observed in the patient studied
here, who presented important neurological problems.
Also cases of pulmonary problems in AIDS are described, some
with rapid deterioration followed by sudden death and others with
spontaneous resolution. This patient did not present any pulmonary
manifestations which are considered, together with the neurological
ones, as the two principal forms of the disease2,13,20,23.
It is important to point out the rarity and the polymorphism of the
cutaneous picture. In its generalized forms, especially in patients who
have AIDS, it presents acneiform injuries, papules, nodules, vesicles,
ulcers, ecchymosis and rarely cellulitis12,20,21,33. It can appear similar to
some dermatological diseases, among which are the following: basal
cell carcinoma, disseminated giant molluscum contagiosum,
paracoccidioidomycosis and histoplasmosis11,20,21. The patient in this
study presented innumerable injuries mimicking molluscum
contagiosum, characterizing a rare exuberant clinical manifestation.
To get a diagnostic of cryptococcosis, it is necessary to research
the Cryptococcus neoformans in suspected organic material, on special
stainings2,20. In the patient in question, this research was done in
fragments of cutaneous injury, blood and cerebrospinal fluid,
confirming the presence of fungus.
It is interesting to note that the positive culture not only serves for
diagnostic purposes, but also as an important auxiliary method in the
follow up of the patient, for evaluation of the viability of fungus, after
the use of antifungal drugs22.
Therefore, the presence of Cryptococcus neoformans in tests carried
out with organic material is enough to determine the diagnosis of
cryptococcosis, as was the case with this patient. However, diverse
complementary methods still exist that can assist it, such as serological
tests, antigen research of fungus and the techniques of polymerase
chain reaction (PCR), intradermic reaction and imunohistochemistry20.
In relation to the therapy, the choice of the drug depends on the
organ involved, as well as on the immune state of the individual30. In
the localized forms, fluconazole can be indicated; whereas in the most
serious cases, amphotericin B must be initially used until there is clinical
improvement and improvement in the cerebrospinal fluid parameters,
including conversion for the negative culture and reduction of the
cryptococcocical antigen headings. Many authors continue with
amphotericin B until the end of the treatment; however, others complete
it with fluconazole30,32. This latter option was chosen for this patient;
however, it was not done regularly with him.
Another optional drug for cryptococcosis is the flucytosine, tested
as monotherapy in patients of good prognosis by HOSPENTHAL &
BENNETT, who demonstrated failure of the treatment in 57% of the
cases; however it is affirmed that this fact would not be related to the
development of resistance to the drug10. Some authors report that
flucytosine does not contribute to the cure, but would only be efficient
in the prevention of recurrences30,32.
In positive HIV, PARISI et al. (1997) show the effectiveness of the
use of amphotericin B together with flucytosin, until clinical
improvement and cerebrospinal fluid complementing the treatment with
itraconazole through the oral duct25. BROUWER et al. in 2004, also
confirms the fast fungicidal action of the two first drugs in
cryptococcical meningitis4.
In negative HIV, BELLOSTA et al. (1999), LACAZ et al. (2002)
and JOSHI et al. (2004) show the effectiveness of isolated fluconazole
in the treatment of primary cutaneous cryptococcosis3,12,21, while
PINTADO et al. (1999) and MELZER et al. (1998) affirm that the
association of amphotericin B and flucytosine generally induces a
favorable reponse in cryptococcosis24,27. KORFEL et al., in 1998, gave
the first account of antimycotic treatment of cryptococcosis with
liposome amphotericin B in patients with Hodgkin’s disease. He affirms
that this drug is less toxic and, perhaps, more effective than the
conventional amphotericin B, especially when cytotoxic treatment is
managed simultaneously17.
On the other hand, it is opportune to make some comments about
those prophylaxis32. Primary prophylaxis is not recommended, due to
the rarity of the illness and the possibility of there occurring interactions
with medicine, particularly in positive HIV patients, who take
innumerable drugs. Secondary prophylaxis shows better results with
fluconazol than that with itraconazol.
Finally, the prognosis of patients with cryptococcosis is poor,
therefore this pathology is associated with immunosuppression. The
evolution does not differ significantly between patients with
disseminated or neurological cryptococcosis22.
The patient in our study had an excellent therapeutic response to
amphotericin B, having been released hospital for a period of time
with important improvement of the neurological and cutaneous picture.
However, this period was relatively short, as he died about 16 months
afterwards, of multiple organ failure, due to probable
neurotoxoplasmosis, without, however, a return of the cutaneous
cryptococcosis. Secondary prophylaxis was not carried out.
CONCLUSION
Cryptococcosis is considered one of the main kinds of systemic
mycosis in AIDS, being the second most common infection of central
nervous system in these patients. The cutaneous form of this fungal
infection is rare, and the differential diagnosis with the disseminated
giant molluscum contagiosum2,21 is particularly important.
Regarding therapy to treat AIDS, there are controversies over the
isolated use of amphotericin B associated with the flucytosine, and
also over whether or not it should be complemented by itraconazole or
fluconazole. The advantages of the latter are its administration through
the mouth and the lesser frequency of collateral effects4,25,30,32.
Thus, early diagnosis and treatment is essential, in which there
can be an improvement in the quality of life of these patients, and
increase in the length of the life span, as well.




Criptococose cutânea disseminada em paciente com SIDA.
Relato de caso
Os autores estudam um paciente portador de SIDA, com
manifestações dermatológicas exuberantes de criptococose. Destacam
a eficácia terapêutica da anfotericina B, a curto prazo. Revisam os
casos de criptococose cutânea relatados na literatura nacional e
internacional, ressaltando o aumento de sua freqüência com a epidemia
da SIDA. Também discutem o diagnóstico diferencial com várias
dermatoses, particularmente com o molusco contagioso gigante
disseminado. Em relação à terapêutica, afirmam que a escolha da droga
depende do órgão comprometido, assim como do estado imunológico
do paciente.
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